Document:

Exhibit 10.4

  

PROMISSORY NOTE

 

$5,000,000.00

 

FOR VALUE RECEIVED,
JetPay Corporation (f/k/a Universal Business Payment Solutions Acquisition Corporation), a Delaware corporation with
its principal place of business at 1175 Lancaster Avenue, Suite 200, Berwyn, PA 19312 (hereinafter the "Maker"), unconditionally
promises to pay to the order of Merrick Bank Corporation, a Utah corporation with offices at 10705
S. Jordan Gateway Ste. 200, South Jordan, Utah 84095 or its assigns (hereinafter "Holder", and, together with
the Maker, the “Parties”), the principal amount of Five Million Dollars ($5,000,000.00), together with all accrued
Interest thereon, as provided in this Promissory Note (the “Note”, as the same may be amended, restated, supplemented
or otherwise modified from time to time in accordance with its terms).

 

This Note is issued
to evidence in part the obligations of the Maker to the Holder pursuant to that certain Settlement Agreement dated the date hereof
(the “Settlement Agreement”) by and among the Maker, the Holder, JetPay Merchant Services, LLC, JetPay ISO Services,
LLC, JetPay, LLC, and WLES, L.P., (“WLES”). Pursuant to the Settlement Agreement, certain shares of the common stock
and cash of the Maker (the “Escrow Fund”) that had previously been or will be placed into escrow to secure certain
pre-existing obligations of Maker’s affiliates to Holder, were pledged by WLES to the Holder to secure the Maker’s
obligations to Holder thereunder including, without limitation, the obligations of Maker under this Note.

 

1.Interest.
The outstanding principal amount of this Note shall bear interest (“Interest”) from [Insert date that is the
91st day after the date hereof] at the rate of twelve percent (12%) per annum (except that Interest on
the outstanding principal amount of this Note from and after the occurrence of any Event of Default hereunder shall accrue at the
rate of fifteen percent (15 %) per annum) until the entire principal amount hereof shall have been paid in full, whether at maturity,
upon acceleration, by prepayment or otherwise. Interest hereunder shall be computed on the basis of a year of 360 days, and the
actual number of days (including the first day but excluding the last day) elapsed.

 

2.Repayment
Provisions. Subject to the provisions of Section 3 below, the outstanding principal amount of this Note, all unpaid interest
accrued thereon, and all other amounts owed to the Holder hereunder shall be due and payable on or before [Insert date that
is the 180th day after the date hereof] ( the “Maturity Date”).

 

3.Prepayments.

 

(a)Optional Prepayments.
The Maker may prepay this Note in whole or in part at any time or from time to time prior to the Maturity Date without penalty
or premium by paying the principal amount to be prepaid together with all Interest accrued thereon (if any) to the date of prepayment.

 

(b)Mandatory Prepayments.
Upon the sale of any of the Escrow Shares, pursuant to the provisions of the Settlement Agreement, all proceeds thereof will be
paid to the Holder as a mandatory pre-payment of this Note until the outstanding principal amount of this Note, all unpaid interest
accrued thereon, and all other amounts owed to the Holder hereunder shall have been paid in full.

 

    1 

     

    

 

4.Other Payment
Provisions. The Maker shall make each payment and pre-payment hereunder not later than 1:00 P.M. (Eastern time) on the day
when due, without offset, in lawful money of the United States of America to the Holder by wire transfer of immediately available
funds to the Holder’s account in accordance with wire transfer instructions to be provided by the Holder to the Maker from
time to time. All payments will be applied first to costs and fees owing hereunder, second to the payment of Interest accrued hereunder
through the date of payment and third to the payment of principal hereof, in such order as Holder may determine in its sole discretion.
If the date for any payment hereunder falls on a day other than a Business Day, then for all purposes of this Note the same shall
be deemed to have fallen on the next following Business Day, and such extension of time shall in such case be included in the computation
of payments of interest. As used herein, “Business Day” shall mean a day other than a Saturday, Sunday or other day
on which commercial banks in New York, NY are authorized or required by law to be closed.

 

5.Events of
Default. The occurrence of any of the following shall constitute an Event of Default hereunder:

 

(a)Failure
to Pay. The Maker fails to pay (i) any principal amount of this Note as and when due; or (ii) accrued Interest or any other
amount as and when due hereunder and fails to cure any unpaid amount within five (5) days of the date said amount was due.

 

(b)Cross-Defaults.
The Maker fails to pay when due any of its indebtedness (other than indebtedness under this Note) or any interest or premium thereon
as and when due (whether by scheduled maturity, acceleration, demand or otherwise) and such failure continues after the applicable
grace period, if any, specified in the agreement or instrument relating to such indebtedness.

 

(c)Breach
of Settlement Agreement.The Maker is in breach of or otherwise fails to comply with any of its obligations under the Settlement
Agreement or any other agreements, notes or instruments executed and delivered by it in connection therewith or otherwise in connection
with the Escrow Fund and fails to cure any such breach or compliance failure within five (5) days of the date of such breach or
failure.

 

(d)Bankruptcy.  

 

(i)the Maker
commences any case, proceeding or other action (A) under any existing or future law relating to bankruptcy, insolvency, reorganization,
or other relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it as bankrupt
or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief
with respect to it or its debts, or (B) seeking appointment of a receiver, trustee, custodian, conservator or other similar official
for it or for all or any substantial part of its assets, or the Maker makes a general assignment for the benefit of its creditors;

 

    2 

     

    

 

(ii)there
is commenced against the Maker any case, proceeding or other action of a nature referred to in clause (i) above which (A) results
in the entry of an order for relief or any such adjudication or appointment or (B) remains undismissed, undischarged or unbonded
for a period of sixty (60) days;

 

(iii)there
is commenced against the Maker any case, proceeding or other action seeking issuance of a warrant of attachment, execution or similar
process against all or any substantial part of its assets which results in the entry of an order for any such relief which has
not been vacated, discharged, or stayed or bonded pending appeal within sixty (60) days from the entry thereof;

 

(iv)the
Maker takes any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth
in clause (i), (ii) or (iii) above; or

 

(v)the Maker
is generally not, or is unable to, or admits in writing its inability to, pay its debts as they become due.

 

(e)Judgments.
A judgment or decree is entered against the Maker and such judgment or decree has not been vacated, discharged, stayed or bonded
pending appeal within thirty (30) days from the entry thereof.

 

6.Remedies.
Upon the occurrence of an Event of Default and at any time thereafter during the continuance of such Event of Default, the Holder
may at its option, by written notice to the Maker (a) declare the entire principal amount of this Note, together with all accrued
interest thereon and all other amounts payable hereunder, immediately due and payable and/or (b) exercise any or all of its rights,
powers or remedies available to it pursuant to the Settlement Agreement or otherwise under applicable law; provided, however
that, if an Event of Default described in Section 5(d) shall occur, the principal of and accrued Interest hereunder shall become
immediately due and payable without any notice, declaration or other act on the part of the Holder.

 

7.Miscellaneous.

 

(a)Notices.
 All notices, requests or other communications required or permitted to be delivered hereunder shall be delivered in writing,
if to the Maker, at the address set forth above, or at such other address as may have been furnished to the Holder by the Maker
in writing; or if to the Holder, to it at the address set forth above, or at such other address as may have been furnished to the
Maker by the Holder in writing. Notices, if (i) mailed by certified or registered mail or sent by hand or overnight courier service
shall be deemed to have been given when received, (ii) sent by facsimile during the recipient's normal business hours shall be
deemed to have been given when sent (and if sent after normal business hours shall be deemed to have been given at the opening
of the recipient's business on the next business day) and (iii) sent by e-mail shall be deemed received upon the sender's receipt
of an acknowledgment from the intended recipient (such as by the "return receipt requested" function, as available, return
e-mail or other written acknowledgment).

 

    3 

     

    

 

(b)Expenses.
The Maker shall reimburse the Holder on demand for all reasonable out-of-pocket costs, expenses and fees (including reasonable
expenses and fees of its counsel) incurred by the Holder in connection with the transactions contemplated hereby including the
negotiation, documentation and execution of this Note and the enforcement of the Holder's rights hereunder.

 

(c)Governing
Law. This Note and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon,
arising out of or relating to this Note and the transactions contemplated hereby shall be governed by the laws of the State of
Utah.

 

(d)Submission
to Jurisdiction.  The Maker hereby irrevocably and unconditionally (i) agrees that any legal action, suit or proceeding
arising out of or relating to this Note may be brought in the Federal District Court in Salt Lake City, Utah and (ii) submits to
the exclusive jurisdiction of such court in any such action, suit or proceeding. Final judgment against the Maker in any action,
suit or proceeding shall be conclusive and may be enforced in any other jurisdiction by suit on the judgment. Nothing in this 7(d)
shall affect the right of the Holder to (i) commence legal proceedings or otherwise sue the Maker in any other court having jurisdiction
over the Maker or (ii) serve process upon the Maker in any manner authorized by the laws of any such jurisdiction.

 

(e)Venue.
The Maker irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any objection that it may
now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Note in any court referred
to in Section (d) and the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.

 

(f)Waiver of
Jury Trial. THE MAKER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO
A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY RELATING TO THIS NOTE OR THE TRANSACTIONS CONTEMPLATED HEREBY WHETHER
BASED ON CONTRACT, TORT OR ANY OTHER THEORY.

 

(g)Counterparts;
Integration; Effectiveness. This Note and any amendments, waivers, consents or supplements hereto may be executed in counterparts,
each of which shall constitute an original, but all taken together shall constitute a single contract. This Note constitutes the
entire contract between the Parties with respect to the subject matter hereof and supersedes all previous agreements and understandings,
oral or written, with respect thereto. Delivery of an executed counterpart of a signature page to this Note by facsimile or in
electronic (i.e., "pdf" or "tif") format shall be effective as delivery of a manually executed counterpart
of this Note.

 

(h)Successors
and Assigns. This Note may be assigned, transferred or negotiated by the Holder to any person or entity at any time without
notice to or the consent of the Maker. The Maker may not assign or transfer this Note or any of its rights hereunder without the
prior written consent of the Holder. This Note shall inure to the benefit of and be binding upon the Parties hereto and their permitted
assigns.

 

    4 

     

    

 

(i)Waiver of
Notice, etc. The Maker hereby waives presentment, demand for payment, protest, notice of dishonor, notice of protest or nonpayment,
notice of acceleration of maturity and diligence in connection with the enforcement of this Note or the taking of any action to
collect sums owing hereunder.

 

(j)Amendments
and Waivers. No term of this Note may be waived, modified or amended except by an instrument in writing signed by both of the
Parties hereto. Any waiver of the terms hereof shall be effective only in the specific instance and for the specific purpose given.

 

(k)Headings.
The headings of the various Sections and subsections herein are for reference only and shall not define, modify, expand or limit
any of the terms or provisions hereof.

 

(l)No Waiver;
Cumulative Remedies. No failure to exercise and no delay in exercising on the part of the Holder, of any right, remedy, power
or privilege hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power
or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and
privileges provided by law.

 

(m)Severability.
If any term or provision of this Note is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or
unenforceability shall not affect any other term or provision of this Note or invalidate or render unenforceable such term or provision
in any other jurisdiction.

 

(n)Replacement
of Note. Upon receipt of evidence reasonably satisfactory to the Maker of the loss, theft, destruction or mutilation of this
Note and, in the case of any such loss, theft or destruction of this Note, upon delivery of an indemnity bond in such reasonable
amount as the Maker may determine, or, in the case of any such mutilation, upon surrender and cancellation of such mutilated Note,
the Maker will execute and deliver, in lieu thereof, a new Note of like tenor and of the same class, dated the date to which interest
has been paid on such lost, stolen, destroyed or mutilated Note.

 

[the balance
of this page is intentionally left blank]

 

    5 

     

    

 

IN WITNESS WHEREOF,
the Maker has caused this Note to be executed by its officer thereunto duly authorized as of the 26 day of July, 2016.

 

	 	JETPAY CORPORATION
	 	 
	 	By: /s/ Peter B. Davidson
	 	Name: Peter B. Davidson
	 	Title: Vice Chairman

 

STATE OF PA     )

	 	)  ss:
	COUNTY OF Philadelphia    	)

 

I, Vincent J. Grandinetti,
hereby certify on this 26 day of July, 2016, before me, the subscriber, a Notary Public of the jurisdiction aforesaid, personally
appeared Peter B. Davidson., known to me (or satisfactorily proven) to be the person whose name is subscribed to the within
instrument as the Vice Chairman of JetPay Corporation and acknowledged that he executed the same on behalf of JetPay Corporation,
for the purposes therein contained, such instrument having been executed in my presence.

 

AS WITNESS my hand
and notarial seal the day and year above written.

  

	 	/s/ Vincent J. Grandinetti
	 	Notary Public

 

My Commission Expires: May 28, 2017

 

    6EXHIBIT 10.30

 

First Amendment to
Licensing Agreement

 

This
First Amendment to Licensing Agreement
("First Amendment")
is to memorialize the agreement between
PharmaCyte Biotech, Inc.,
formerly Nuvilex, Inc.
("Licensee")
and Austrianova Singapore Pte Ltd ("Licensor")
to amend, effective as
of June 30, 2015, the Licensing
Agreement between the parties dated
as of 1 December 2014 ("Licensing
Agreement") as follows.
The defined terms in the Licensing Agreement
have the same meaning
as the terms in this
First Amendment.

 

		A.	The Parties entered into
the Licensing Agreement to,
among other things provide
Licensee with an exclusive worldwide license
to use the Cell-in-a-Box® Trademark and
its Associated Technology with
genetically modified non-stem cell
lines specifically
designed to activate
members of the Cannabinoid
family of molecules
to: (i) conduct research; (ii) have
made by Licensor; (iii)
use in preclinical studies and clinical trials;
(iv) obtain marketing approval;
(v) and market and
sell products and treatments
utilizing the Cell-in-a-Box®
Trademark and its Associated
Technology world-wide;

 

		B.	The Licensing Agreement provides
Licensee shall pay
Licensor an initial payment
("Upfront Payment") of
Two Million Dollars US (USD $2,000,000 .00.
It further provides
that Licensee shall make periodic
monthly partial payments of the
Upfront Payment in amounts to be
agreed upon between the Parties prior to each such payment
being made; provided, however the Upfront Payment shall
be paid in full by
no later than June 30,
2015.; and

 

		C.	The Parties desire to extend
the date by which
the Upfront Payment
must be made by Licensee.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt
and sufficiency of which are hereby
acknowledged by the Parties,
the Research Agreement is hereby
amended as follows:

 

1.  
Section 2.2 of
the Licensing Agreement shall be
deleted and the following inserted in its place:
"Subject to the
terms of this Agreement ,
Licensee shall pay Licensor
an initial payment ("Upfront
Payment") of Two
Million Dollars US (USD
$2,000,000.00).
Licensee shall make periodic monthly
partial payments of the Upfront Payment in amounts
to be agreed upon between
the Parties prior to each
such payment being made: provided,
however, the Upfront
Payment shall be paid in full by
no later than December
31, 2015."

 

2.  
Section 8.1.2.
of the Licensing Agreement
shall be deleted and the following inserted in its
place: "Similarly,
the License may be
terminated and all rights
shall revert to Licensor if any
of the following events do not occur within the
timeframe set forth in
this Agreement provided that
Licensor gives Licensee thirty (30)
days' notice prior
to the effective date of termination and Licensee
fails to cure the following events
during the thirty (30)
day period: (i)
if Licensee fails to
pay in full the Upfront
Payment by December 31,
2015; (ii) if Licensee does not enter
into a research program
involving the Scope
of the Agreement within three (3) years of the Effective
Date; or (iii) if
Licensee does not enter
clinical trials or their equivalent for a Product within seven
(7) years from the Effective Date."

 

3.   
Except as provided
in this First Amendment , all
of the other provisions of the
Licensing Agreement shall remain in full force and
effect.

 

IN
WITNESS WHEREOF , each Party
has executed this First
Amendment by its duly authorized representative
as of the date first
written above.

 

 

	PharmaCyte Biotech, Inc.	Austrianova
Singapore Pte Ltd
	 	 
	/s/ Kenneth L. Waggoner               	/s/ Brian Salmons              
	By: Dr. Kenneth L. Waggoner

                                    Title:
Chief Executive Officer

                                    
	By:

        Title:
	Dr. Brian Salmons
 Chief
Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}]]